Bryant v. Stein et al.

Why this Matters:

The plaintiff alleges that North Carolina’s legislation, which imposes several requirements to access and prescribe mifepristone, conflicts with the Food and Drug Administration’s (FDA’s) exclusive authority to impose restrictions on the prescribing, dispensing and administration of drugs. Ensuring that individuals have access to FDA-approved medication abortions enables patients to receive necessary reproductive health care.

Potential Impact:

Overriding the FDA’s expertise and preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety.